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Abstract
Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is X-linked recessive lysosomal storage disorder resulting
from the defective activity of the enzyme iduronate-2-sulfatase (IDS). Hunter disease can vary from mild to severe,
depending on the level of enzyme deficiency. We report the IDS mutation and polymorphisms causing the Hunter
syndrome in patients from one family in Tunisia
Patients and methods: A preliminary diagnosis was made by qualitative detection of urinary glycosaminoglycans
of the suspected MPS II probands. The IDS mutation and polymorphisms were determined on these probands and
their family members by amplifying and sequencing each of the exons and intron-exon junctions of IDS gene.
Results: The studied probands were homoallelic for p.R88P mutation. In addition, three known polymorphisms/
sequence variants: IVS3-16 (c.419-16 delT), T214M (c.641C > T), T146T (c.438 C > T), IVS5-87(c.709-87G > A) and one
previously unknown: IVS7+38(c.1006+38T > C were identified in the MPS II patients. These are the first Tunisian
MPS II patients to be genotyped.
Conclusion: The identification of these mutation and polymorphisms and their genotype-phenotype correlation
should facilitate prenatal diagnosis and counseling for MPS II in Tunisia, where a very high rate of consanguinity
exists.
Introduction
Mucopolysaccharidosis type II (MIM 309900) is X-linked
recessive lysosomal storage disorder caused by the defi-
cient of the enzyme iduronate 2-sulfatase (IDS, EC
3.1.6.13). This glycosidase is required for the hydrolysis
of the 2-sulfate groups of the L-iduronate 2-sulfate units
of dermatan sulfate and heparan sulfate [1]. Deficiency of
this enzyme causes accumulation and higher urine excre-
tion of these undegraded substrates in lysosomes leading
to cell death and to the clinical manifestations of the dis-
ease. A wide spectrum of clinical severity is recognized in
MPS II. Severely affected individuals usually die between
10 and 15 years of age, although some die much earlier.
Individuals with mild forms of MPS II can have signifi-
cant somatic disease, but reasonably normal life spans.
The treatments for affected individuals were bone mar-
row [2] and enzyme replacement therapy [3]. A prelimin-
ary diagnosis was made by qualitative detection of
urinary glycosaminoglycans of the suspected MPS II pro-
band, then, confirmed by the demonstration of deficient
iduronate 2 sulfatase activity in leukocytes, plasma or cul-
tured cells. The IDS gene is situated on the telomere of
the long arm of chromosome X at region Xq28 [4]. Two
forms of IDS were identified from human placenta [5]
and 2 major forms of iduronate sulfatase were purified
with molecular masses of 42 kD and 14 kD [6]. The gene
has 9 exons and produces a transcript of 1.4 that encodes
a precursor protein of 550 amino acide [7]. More than
300 different mutations in the IDS gene had been
reported in patients with Hunter syndrome [8] including
gene rearrangements caused by recombination with the
IDS2 pseudogene, deletions of certain exons or the entire
IDS gene or small mutations including insertions, dele-
tions and point mutations that created a novel splice site.
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Mucopolysaccharidosis type II has two major clinical
phenotypes, ranging the severe form called MPS IIA to
the mild form called MPS IIB:
T h es e v e r ef o r m( M P SI I A ) ,t h ec h i l di sn o r m a la t
birth, and symptoms appear gradually. The diagnosis is
usually referred to between 2 and 4 years. The MPS IIA
patient is characterized by progressive mental retarda-
tion, physical disability, severe airway obstruction, skele-
tal deformities, cardiomyopathy, and, in most patients,
neurologic decline. Death usually occurs at age of 15
years in most cases.
T h em i l df o r m( M P SI I B ) ,t h ec l i n i c a ls y m p t o m
appears after 10 years of age. At this age, the MPS IIB
patient had normal growth and development. He had
mild dysostosis radiologically, coarse facial features, flex-
ion contractures of the elbows and shoulder joints,
moderate hepatosplenomegaly and a long life span with
and a long life span with minimally impaired neurologi-
cal. A lack of opacification of the cornea was noted in
the MPS II as opposed to the MPS I [10].
This inherited disease may constitute a relatively more
important social and economic concern in Tunisia
because of the prevalence of first-cousin marriages [11].
Thus, the identification of the IDS mutations causing
MPS II in Tunisia is important for prenatal diagnosis in
affected families. Here, we report the IDS mutation and
polymorphisms causing the Hunter syndrome in
patients from one family in Tunisia.
Patients and methods
Patients
One family from Tunisia with MPS II was investigated.
The MPS II patients were diagnosed in paediatric
department of center Tunisia.
This family gave birth for 3 affected children (Figure
1). The first patient was died before our investigation at
on age of seven years. The other two boys: the patient 2
was diagnosed at the age of three years when he was
operated for inguinal hernia. Coarse facial feature
including macrocrania, macroglossia and small teeth
a n dp o o r l yi m p l e m e n t e dw e r en o t e da ta na g eo fe i g h -
teen months. He had a short stature (-4DS), hepatosple-
nomegaly, skeletal disease and he had developed
progressive mental retardation. Then, he deceased as a
result of cardiorespiratory disease. The patient 3 was
developed similar coarse facial features at the age of
eighteen months. He showed severe developmental
delay, hydrocephaly, deafness and inguinal hernia.
The MPS II patients were offspring of consanguineous
marriage between first cousins (Figure 1). Blood samples
were collected from the patients, their parents, and
unaffected siblings and relatives. The clinical diagnosis
was confirmed enzymatically (Table 1). This study was
approved by the Ethnics Committees of the Tunisian
Hospital and the parents gave full informed consent.
IDS activity and Mutation analysis
IDS activity was determined in sonicated leukocytes pel-
lets as described using the artificial substrate 4-methy-
lumbelliferyl-alpha-iduronide-2-sulfate [12]. For IDS
mutation analysis, genomic DNA was extracted from
peripheral blood leukocytes by the phenol-chloroform
procedure. Each of the 9 exon and intron-exon bound-
aries of IDS gene were amplified from genomic DNA
from the patient and her parents as described previously
[13]. The typical PCR reaction was carried out in a 50
μl total volume containing 100 ng of genomic DNA, 0.2
mmol/L dNTPs, 0.4 μM of each primer, 1.5 mmol/L
MgCl2, 10% (V/V) DMSO and 0.15 μl( 0 . 7 5u n i t s )o f
Taq polymerase (Bromega).
Results
Clinical findings: the clinical features of MPS II patients
and their leukocyte IDS activity are presented in Table 1.
IDS mutation analysis
The patients from southern Tunisia were homozygous
for a G to C transversion in exon 3 predicting an argi-
nine to a proline missense mutation p.R88P. In addition,
five sequence variants, including four previously
reported polymorphisms, were detected. The unreported
polymorphisms was IVS7+38 (c.1006+38T > C). The
previously described polymorphisms were IVS3-16
(c.419-16 delT), T146T (c.438 C > T), T214M (c.641C >
T), IVS5-87(c.709-87G > A) (Table 2).
Figure 1 Pedigree of studied family. Square and circles indicate
male and female members, respectively. Shaded symbols indicate
affected individuals.
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Estimates of the incidence of MPS II in European and
Anglo-Saxon countries range from 1:55 000 to 1:160
250 male newborns [14-20]. It is the most common type
of MPS in Taiwan and northern Asia [21,22].
In Tunisia, the global incidence of all the MPS is 2.3/
100.000 lives births [23]. A prevalence of different types
of mucopolysaccharidoses was evaluated as the MPS
type I, III and IV [24] but that of type II is unknown
due the ignorance of some clinical picture.
Furthermore, MPS II is expected to be found only in
males, but some females have been reported [25,26].
The diagnosis of MPS II patients was made by
demonstrating an increased amount of urinary heparan
sulfate and dermatan sulfate, and very low residual IDS
activity in peripheral blood leukocytes.
According to the HGMD database, to date, more than
300 different mutations in the IDS gene had been
reported in patients with Hunter syndrome (Human
Gene Mutation Database; http://www.hgmd.org). The
mutational spectrum associated with the IDS gene is
quite heterogeneous and ranges from point mutations to
large-scale gene conversion or deletion. The majority of
mutations are missense and nonsense mutation, and
approximately 15% of mutations are presumed to be
caused by a gross deletion.
This study identified the first IDS mutation in Tuni-
sian patients with the Hunter syndrome. These patients,
whose were born to consanguineous parents, were
homozygous for the previously described p.R88P mis-
sens mutation [27]. The p.R88P mutation resulted in the
replacement of a basic arginine with a neutral proline. A
non conservative substitution could be predicted to
drastically change the orientation of the secondary
structure in IDS protein. This mutation causes a sever
instability or loss of IDS protein function leading to a
severe disease.
Homology analyses revealed that arginine-88 is highly
conserved among the human and eukaryotic sulfatases
(Figure 2). The structure of human IDS was modeled by
homology with crustal structure of human N-actyl-
galactosamine-4-sulfatase (4S) and arysulfatase A (ASA)
Table 1 the clinical features of MPS II patients and their leukocyte IDS activity
Features Family 1
Patient 1 Patient 2
MPS II genotype p.R88P p.R88P




Age at diagnosis (year/month) 3 years 3 years
Age of onset (year/month) 18 months 18 months
Sex Male Male




skeletal deformities severe severe
Other features teeth small and poorly located deafness teeth small and poorly located deafness
Mental retardation severe severe
IDS activity nmol/h/mg protein 2 5
Table 2 Mutation and polymorphisms in MPS II patient





c.438 C > T
4 [31]
p.R88P G > C 263 88 3 [28] T214M
c.641 C > T
5
IVS5-87
c.709-87 G > A
6
IVS7+38
c.1006+38 T > C
7 This report
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for processing but important for IDS conformation [29].
R88 residue is found adjacent to the active site residue,
C84, and is a part of the core of the major domain of
I D S .T h ea l t e r a t i o nb yp r o l i n e ,am o r eb u l k yh y d r o p h o -
bic residue, can affect the stability of the major domain
structure. The side-chain of R88 stretches in the oppo-
site direction from the active site and arginine has a
hydrophobic root in its side-chain. Thus, the substitu-
tion of R88 by a smaller hydrophobic residue, proline,
could be tolerated (Figure 3).
In the present study, five IDS sequence variants (IVS3-
16 (c.419-16 delT), T214M (c.641C > T), T146T (c.438
C > T), IVS5-87(c.709-87G > A). have been identified in
Tunisian MPS II patients, including one novel poly-
morphism (IVS7+38 (c.1006+38T > C). Since the T146T
substitution has frequently been described as a poly-
morphism site [30]. This modification was identified in
homozygous state in patient with a severe phenotype
[31] and also in patient with mild phenotype [13]. Our

Figure 2 Comparison of the homology of eukaryotic sulfatase. Human Arginine 88 and homologous Arginine are indicated in pink and
boxed.
Figure 3 Location of mutated residue (Arg88) in a tertiary
structural model of IDS. The active site centre, Cys84 residue, is
shown as green spheres and the other active site residues are
shown as different spheres colors.
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a previously reported p.R88P mutation and others
described polymorphisms and unreported
polymorphism.
The effect of these polymorphisms on the expression
of IDS is unknown. Further studies on large number of
MPS II patients and normal population might help in
finding out whether these variants are associated with
MPS II or not. Moreover, the correlation between geno-
type and phenotype has remained unclear.
We note a considerable heterogeneity of MPS I [32]
and MPS IVA [33] mutations in Tunisia; we also esti-
mate that more mutations could be potentially present
in the population.
The identification of a large battery of mutations in
MPS patients including MPS I, MPS II and MPS IVA
patients and the possibility of their early detection
represent a cornerstone for the establishment of MPS
prevention program in Tunisia based on prenatal
diagnosis.
Conclusion
In conclusion, this is the first report of IDS mutation in
Tunisian patients with MPS II. We applied the following
strategy: An accurate biochemical test is available for the
diagnosis of Hunter disease consisting of the demonstra-
tion on deficient IDS activity in leucocytes. This test was
performed before molecular analysis. Molecular identifi-
cation of the mutation in individuals with a confirmed
diagnosis can be used for carrier detection of the
females in family at risque and prenatal diagnosis.
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